Merger and acquisition (M&A) transactions remain prevalent in the medical device manufacturing industry in many forms—larger organizations making bolt-on acquisitions of smaller, innovative companies and/or businesses, mergers of equals, private equity deals, and medical product outsourcing providers grabbing specialty businesses to round out their offerings on the journey to full service.

To help our readers stay up to date about the medical device market’s evolution, MPO will catalog these M&A transactions throughout the year. We hope this will be a helpful resource!

MGS-Knudsen Plast A/S

MGS announced its acquisition of Denmark-based injection molder Knudsen Plast A/S, an organization with more than four decades of healthcare manufacturing experience. 
Date of Announcement: February 23, 2026
Value: Not disclosed
More info

Danaher—Masimo

Masimo develops patient monitoring devices, non-invasive sensors, and related software platforms used in hospital and home settings. It will become a become a standalone, autonomously operating business unit and brand in Danaher’s Diagnostics segment.
Date of Announcement: February 17, 2026
Value: $180 per share in cash ($9.9 billion)
More info

Vygon—Avia Vascular’s Stiletto

Vygon has acquired Stiletto, a new generation of extended‑dwell catheters integrating SlipStream technology, from Salt Lake City-based Avia Vascular.
Date of Announcement: Feb. 11, 2026
Value: Not disclosed
More info

Medtronic—CathWorks

Privately-held CathWorks bolsters Medtronic’s catheterization technological prowess. The medical device giant has held a minority stake in the Israeli diagnostics firm since 2018.
Date of Announcement: Feb. 3, 2026
Value: Up to $585 million, potential earn-out payments once deal is complete
More info

Invio Automation—Calvary Robotics Inc.

Together, the combined business will be able to better serve the complex automation and high-precision system needs of customers from concept and simulation through build, deployment, and continuous optimization.
Date of Announcement: Feb. 2, 2026
Value: Not disclosed
More info

Symmetry Laser—ArcRev

ArcRev adds complementary laser cutting tech, technical talent, and disciplined operating practices aligned with Symmetry’s manufacturing approach.
Date of Announcement: January 28, 2026
Value: Not disclosed
More info

Resonetics—Resolution Medical

Resolution provides of integrated design and manufacturing solutions for complex medical devices—it adds complementary capabilities of neuromodulation, structural heart, and interventional cardiology.
Date of Announcement: January 27, 2026
Value: Not disclosed
More info

BioStem Technologies—BioTissue Holdings’ Surgical and Wound Care Business

The deal expands access to major GPO networks, strengthening BioStem’s position across hospital settings.
Date of Announcement: January 21, 2026
Value: $15 million upfront cash payment, potential for additional regulatory milestone payment of up to $10 million for 510(k) clearance for a new product, potential commercial royalty milestone payments of up to $15 million
More info

Boston Scientific—Penumbra

Penumbra provides mechanical thrombectomy products that are used in peripheral vascular procedures to remove blood clots.
Date of Announcement: January 15, 2026
Value: $374 per share, $14.5 billion enterprise value
More info

Boston Scientific—Valencia Technologies

Valencia’s eCoin system is an implantable tibial nerve stimulation device to treat urinary urge incontinence, a common symptom of overactive bladder.
Date of Announcement: January 12, 2026
Value: Not disclosed
More info

Edwards—JenaValve (Terminated)

The U.S. District Court for the District of Columbia granted the motion from the U.S. Federal Trade Commission (FTC) for an injunction to block the company’s proposed acquisition of JenaValve.
Date of Announcement: January 9, 2026
More info

Haemonetics—Vivasure

Vivasure’s PerQseal Elite system uses a proprietary bioabsorbable patch to seal large-bore (up to 26F) arteriotomies and venotomies from inside the vessel.
Date of Announcement: January 9, 2026
Value: Up to €185 million
More info

NAMSA—Labcorp

NAMSA will assume the U.S. portfolio of services of Labcorp’s Early Development medical device business, including biocompatibility testing, microbiological testing, analytical testing, and preclinical research.
Date of Announcement: January 8, 2026
Value: Not disclosed
More info

Arterex—Synecco

Synecco is based in Ireland and boasts expertise in the structural heart space, with the addition of injection molding and assembly capabilities.
Date of Announcement: January 6, 2026
Value: Not disclosed
More info

Alcon—STAAR Surgical (Terminated)

STAAR did not receive the necessary stockholder votes to approve the merger agreement with Alcon at its Special Meeting of Stockholders, resulting in termination.
Date of Announcement: January 6, 2026
More info

Resonetics—Med-Ally

This deal includes manufacturing assets, process know-how, and intellectual property related to implantable and external pulse generators as well as leads manufacturing and assembly.
Date of Announcement: January 6, 2026
Value: Not disclosed
More info

W.L. Gore & Associates (Gore)—Conformal Medical

Conformal Medical develops the investigational CLAAS AcuFORM system, a next-gen left atrial appendage occlusion (LAAO) device.
Date of Announcement: January 5, 2026
Value: Not disclosed
More info

Year-by-Year

2025 Medical Device Companies M&A Roundup
2024 Medical Device Manufacturing M&A Roundup